.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 3,666,858

« Back to Dashboard

Claims for Patent: 3,666,858

Title: UTILIZATION OF GON-4-ENE THERAPY IN TREATMENT OF FEMALES AND IN GROWTH STIMULATION
Abstract:Methods of using certain 13-ethyl-gon-4-enes are described, namely 13.beta.,17.alpha.-diethyl-17.beta.-hydroxygon-4-en-3-one, and the decanoate ester of 13.beta.-ethyl-17.beta.-hydroxygon-4-en-3-one for growth stimulation in mammals; and 13.beta.-ethyl-17.alpha.-ethynyl-17.beta.-hydroxygon-4-en-3-one, to treat dysfunctions of the female reproductive system in mammals, to control cyclic regularity, and to prevent conception in female mammals.
Inventor(s): Hughes; Gordon Alan (Haverford, PA), Smith; Herchel (Wayne, PA)
Assignee: SAID Smith, by said Hughes (N/A)
Application Number:04/649,800
Patent Claims: 1. A composition, useful for stimulating growth of a mammal, comprising an effective growth-stimulating amount of a compound, selected from the group consisting of 13.beta., 17.alpha.-diethyl-17.beta.-hydroxygon-4-en-3-one and 13.beta.-ethyl-17.beta.-hydroxygon-4-en-3-one 17-decanoate, and a pharmaceutically acceptable carrier.

2. A composition, useful for cyclic control in a female mammal, and for treatment of dysfunctions of the female reproductive system in a mammal, said dysfunctions being selected from the group consisting of amenorrhea, dysmenorrhea, and functional uterine bleeding, comprising an amount of 13.beta.-ethyl-17.alpha.-ethynyl-17.eta.-hydroxygon-4-en-3-one effective for the said purpose and a pharmaceutically acceptable carrier.

3. Composition of claim 2, wherein the amount of 13.beta.-ethyl-17.alpha.-ethynyl-17.beta.-hydroxygon-4-en-3-one is about 2.5 to about 25 mg.

4. A composition, useful for preventing conception in a female mammal, comprising an amount of 13.beta.-ethyl-17.alpha.-ethynyl-17.beta.-hydroxygon-4-en-3-one between about 0.015 and about 10 mg., effective for said purpose and a pharmaceutically acceptable carrier.

5. Composition of claim 4, wherein the amount of 13.beta.-ethyl-17.alpha.-ethynyl-17.beta.-hydroxygon-4-en-3-one is about 0.015 to about 1 mg.

6. A composition, useful for preventing conception in a female mammal, comprising an amount of 13.beta.-ethyl-17.alpha.-ethynyl-17.beta.-hydroxygon-4-en-3-one effective to prevent conception and up to about 0.05 mg. of ethynyl estradiol.

7. A method of stimulating growth in a mammal which comprises administering to said mammal a growth stimulating amount of 13.beta., 17.alpha.-diethyl-17.beta.-hydroxygon-4-en-3-one.

8. A method of stimulating growth in a mammal which comprises administering to said mammal a growth stimulating amount of 13.beta.-ethyl-17.beta.-hydroxygon-4-en-3-one 17-decanoate.

9. A method for cyclic control in a female mammal and treatment of dysfunctions of the female reproductive system in a mammal, said dysfunctions being selected from the group consisting of amenorrhea, dysmenorrhea, and functional uterine bleeding, which comprises orally administering to said mammal a pharmaceutically effective amount of 13.beta.-ethyl-17.alpha.-ethynyl-17.beta.-hydroxygon-4-en-3-one.

10. A method of preventing conception in a female mammal which comprises orally administering to said mammal 13.beta.-ethyl-17.alpha.-ethynyl-17.beta.-hydroxygon-4-en-3-one in an effective amount of 0.015 mg. to about 10 mg. per day.

11. A method of preventing conception in a female mammal which comprises orally administering to said mammal an effective amount of about 0.015 mg. to about 1 mg. per day of 13.beta.-ethyl-17.alpha.-ethynyl-17.beta.-hydroxygon-4-en-3-one on a continuous basis.

12. A method of preventing conception in a female mammal which comprises orally administering to said mammal an amount of 13.beta.-ethyl-17.alpha.-ethynyl-17.beta.-hydroxygon-4-en-3-one effective to prevent conception in combination with up to about .05 mg. of ethynyl estradiol per day on a cyclic basis.

13. A method for control of gynecomastia in a male human which comprises administering to said male human an amount of 13.beta.-ethyl-17.alpha.-ethynyl-17.beta.-hydroxygon-4-en-3-one effective for said purpose.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc